Running Out of Options: Managing Refractory Septic Shock
Dr Samir S. Awad presents a patient case and holds panel discussion on vasopressor escalation strategy at our symposium at SCCM 2026.
VIDEOS & RESOURCES
CLINICAL PERSPECTIVES
ON VASODILATORY SHOCK
Jump to:
Expert video series
Critical views:
Leading voices IN VASODILATORY SHOCK
VIDEOS ON HYPOTENSION MANAGEMENT IN SEPTIC SHOCK
Septic Shock: Different Patients, Different Vasopressors
Dr Richard G. Wunderink presents a patient case and holds panel discussion on guiding treatment by perfusion markers at our symposium at SCCM 2026.
VIDEOS ON HYPOTENSION MANAGEMENT IN perioperative VASOPLEGIA
Identifying High-Risk Patients Before CPB
Dr Rawn Salenger reviews patient and operative characteristics associated with vasoplegia in cardiac surgeries.
Why Early Escalation Timing Matters
Dr Rawn Salenger explains the ramifications of patients falling below a MAP of 65 mmHg post CPB.
A Targeted Approach for Patients With Refractory Shock
Dr Rawn Salenger talks about his experience with using GIAPREZA post CPB.
Post-Bypass Vasoplegia: A Distinct Shock Phenotype
Dr David W. Boldt presents a patient case and holds panel discussion on addressing ANG II deficiency after cardiac surgeries at our symposium at SCCM 2026.
Meet the experts
Rawn Salenger, MD
Associate Professor of Surgery
University of Maryland School of Medicine, Baltimore, MD
Samir S. Awad, MD, MPH, FACS
Chief of Surgery and Medical Director Surgical Intensive Care Unit
Michael E. DeBakey VA Medical Center, Houston, TX
Richard G. Wunderink, MD, MS
Professor of Medicine, Pulmonary and Critical Care
Northwestern University Feinberg
School of Medicine, Chicago, IL
David W. Boldt, MD, MS
Chief, Division of Trauma and Adult Multi-Specialty Anesthesiology
University of California,
Los Angeles, CA
MOA Video
Watch how GIAPREZA works
PDF RESOURCES
Download resources to support your use of GIAPREZA
in vasodilatory shock
Ordering Sheet
Download
DOSING & Administration GUIDE
Download
Perioperative Vasoplegia Protocol
Download
ACUTE KIDNEY INJURY SUBGROUP ANALYSIS
Download
RAAS PATHWAY BROCHURE
Download
Septic Shock Brochure
Download
Vasoplegia Brochure
Download
Wastage & warranty information sheet
Download
0.5mg/mL vial quick guide
DownloadConnect with a GIAPREZA sales
REP FOR INFO
and support.
ANG=angiotensin; CPB=cardiopulmonary bypass; MAP=mean arterial pressure; MOA=mechanism of action; RAAS=renin-angiotensin-aldosterone system; SCCM=Society of Critical Care Medicine.
INDICATION
GIAPREZA® (angiotensin II) increases blood pressure in adults with septic or other distributive shock.
IMPORTANT SAFETY INFORMATION
Warnings and Precautions
The safety of GIAPREZA was evaluated in 321 adults with septic or other distributive shock in a randomized, double-blind, placebo-controlled study, ATHOS-3. There was a higher incidence of arterial and venous thrombotic and thromboembolic events in patients who received GIAPREZA compared to placebo-treated patients in the ATHOS-3 study (13% vs. 5%). The major imbalance was in deep venous thromboses. Use concurrent venous thromboembolism (VTE) prophylaxis.
Adverse Reactions
The most common adverse reactions reported in greater than 10% of GIAPREZA-treated patients were thromboembolic events. Adverse reactions occurring in ≥4% of patients treated with GIAPREZA and ≥1.5% more often than placebo-treated patients in the ATHOS-3 study were thromboembolic events (including deep vein thrombosis), thrombocytopenia, tachycardia, fungal infection, delirium, acidosis, hyperglycemia, and peripheral ischemia.
Drug Interactions
Angiotensin converting enzyme (ACE) inhibitors may increase response to GIAPREZA. Angiotensin II receptor blockers (ARBs) may reduce response to GIAPREZA.
You are encouraged to report negative side effects of prescription drugs to the FDA. To report SUSPECTED ADVERSE REACTIONS, please contact:
Before administering, please see the Full Prescribing Information for GIAPREZA.